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Abstract
Sporadic inclusion body myositis (sIBM) is one of the most common myopathies in elderly people. Mitochondrial
abnormalities at the histological level are present in these patients. We hypothesize that mitochondrial dysfunction
may play a role in disease aetiology. We took the following measurements of muscle and peripheral blood
mononuclear cells (PBMCs) from 30 sIBM patients and 38 age- and gender-paired controls: mitochondrial
DNA (mtDNA) deletions, amount of mtDNA and mtRNA, mitochondrial protein synthesis, mitochondrial respiratory
chain (MRC) complex I and IV enzymatic activity, mitochondrial mass, oxidative stress and mitochondrial dynamics
(mitofusin 2 and optic atrophy 1 levels). Depletion of mtDNA was present in muscle from sIBM patients and PBMCs
showed deregulated expression of mitochondrial proteins in oxidative phosphorylation. MRC complex IV/citrate
synthase activity was significantly decreased in both tissues and mitochondrial dynamics were affected in muscle.
Depletion of mtDNA was significantly more severe in patients with mtDNA deletions, which also presented
deregulation of mitochondrial fusion proteins. Imbalance in mitochondrial dynamics in muscle was associated with
increased mitochondrial genetic disturbances (both depletion and deletions), demonstrating that proper
mitochondrial turnover is essential for mitochondrial homoeostasis and muscle function in these patients.
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INTRODUCTION
Sporadic inclusion body myositis (sIBM) is the most common in-
flammatory myopathy in individuals aged >50 years [1] and one
of the most important myopathies associated with ageing [2].
With a male:female ratio of 3:1, it is a rare disease (ORPHA611)
and its prevalence varies from 4.7 per million in the Netherlands
to 14.9 per million in western Australia [3]. These rates continue
Abbreviations: CK, creatine kinase; COX, cytochrome c oxidase; CS, citrate synthase; H&E, haematoxylin and eosin; HAE, hydroxyalkenal; IBMFRS, Inclusion Body Myositis Functional
Rating Scale; MDA, malondialdehyde; MFN2, mitofusin 2; MRC, mitochondrial respiratory chain; NSE, non-specific esterase; OPA1, optic atrophy 1; ORO, Oil Red O; PAS-D, periodic
acid–Schiff diastase stain; PBMC, peripheral blood mononuclear cell; RT-PCR, reverse transcriptase PCR; ROS, reactive oxygen species; SDH, succinate dehydrogenase; sIBM,
sporadic inclusion body myositis; TRC, tyrosine-rich crystalloids; VDAC1, voltage-dependent anion channel 1.
Correspondence: Glòria Garrabou Tornos (email garrabou@clinic.ub.es).
to increase, probably due to improved diagnostic protocols and
increased ageing of the population. This myopathy is a devast-
ating condition, causing slow, progressive muscle weakness and
wasting, with quadriceps and finger flexors being the muscles
most typically affected. Nevertheless, the clinical presentation
varies considerably. This muscle weakness usually leads to falls
and difficulty in standing. Around 60% of the patients also
present with dysphagia. With the wide spectrum of clinical
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manifestations in sIBM, muscle biopsy continues to be the gold
standard for diagnosis [4].
The histological features observed in muscle biopsies of sIBM
patients include: (i) inflammatory changes with predominant
CD8+ T-cell infiltrates and the expression of MHC-I antigens by
non-necrotic muscle fibres, (ii) different degrees of degenerative
changes in muscle fibres and the presence of rimmed vacuoles
composed mainly of β-amyloid, phosphorylated tau and cave-
olin proteins, among others, and (iii) mitochondrial abnormalities
characterized by the presence of ragged-red fibres, cytochrome
c oxidase (COX)-negative and succinate dehydrogenase (SDH)-
positive muscle cells [5,6], all of which are widely associated
with mitochondrial dysfunction and ageing [1,2,7]. However, the
distribution of these histological features is not homogeneous,
and they may not be simultaneously present, particularly in the
early stages of the disease. For all these reasons, and due to its
slow progression, diagnosis may be delayed for 5–10 years.
Mitochondria are the cell’s powerhouse. They are respons-
ible for most of the energy supply, metabolic reactions, calcium
homoeostasis and cell respiration. However, under pathological
conditions, mitochondria are the main centres for reactive oxy-
gen species (ROS) production and for triggering apoptosis. Mito-
chondria are essential for cell bioenergetics, especially in highly
energetic tissues such as muscle, in which mitochondrial dysfunc-
tion may become evident much earlier. Molecular mitochondrial
alterations have recently been found in sIBM by down-regulated
expression of mitochondrial respiratory chain (MRC) complex
I subunits and mitochondrial DNA (mtDNA) variations [7]. In
addition, mtDNA deletions have also been reported in sIBM
patients [6,8], but not correlated with abnormal mitochondrial
function or dynamics. Despite mitochondrial abnormalities hav-
ing classically been described at a histological level, mitochon-
drial dysfunction in sIBM patients has scarcely been assessed at
a molecular level.
Mitochondrial dynamics is a recently discovered mechanism
responsible for mitochondrial turnover and renewal [9]. Mito-
chondria constitute a complex network that is constantly under-
going fusion and fission processes to exchange genetic and struc-
tural components, which include mtDNA and MRC machinery.
Deregulation of mitochondrial dynamics has been associated with
disease, but has not previously been described in sIBM patients
[10–16].
Although the pathological features of sIBM have been widely
described, its aetiology remains unknown. It has been proposed
that its development could be due to a complex interaction of en-
vironmental agents, accelerated ageing and genetic susceptibility
[2,17]. As muscle tissue has a high dependence on ATP to exert
its function, mitochondrial alterations in sIBM could be one of
the factors involved in triggering muscle weakness and degen-
eration, because these alterations have been related to muscle
disease by many authors [18–20]. For an in-depth evaluation of
the pathological characteristics of the disease, we describe the
mitochondrial phenotype at a genetic, molecular and functional
level in sIBM patients.
To determine potential disease biomarkers we assessed ab-
normal mitochondrial fingerprints, in the target tissue of the
disease (muscle) and with less invasive approaches using peri-
pheral blood mononuclear cells (PBMCs). This PBMC model
is widely feasible for the evaluation of mitochondrial func-
tion [21–23]. Thus, we designed the present study to evalu-
ate mitochondrial dysfunction in both muscle and PBMCs of
sIBM patients to correlate dysfunction severity with genetic
and molecular mitochondrial alterations, and determine their




We performed a single-site, cross-sectional, case–control, obser-
vational study.
Study population, diagnosis, clinical data and sample
collection
A total of 30 patients with sIBM who had attended the Internal
Medicine Department of the Hospital Clinic of Barcelona (Spain)
over the last 20 years were prospectively and consecutively in-
cluded. These patients were age and gender paired with 38 con-
trols. All muscle biopsies were performed for diagnostic purposes
indicated for muscle weakness or raised creatine kinase (CK)
levels. Surgical muscle biopsies were obtained by trained physi-
cians, and the samples were processed routinely in the laboratory
as described elsewhere [24]. For histological studies fresh muscle
samples were frozen in cooled isopentane, sectioned by cryotome
at −30 ◦C and stained with different reagents for diagnostic pur-
poses: haematoxylin and eosin (H&E), tyrosine-rich crystalloids
(TRCs), non-specific esterase (NSE), periodic acid–Schiff dia-
stase stain (PAS-D), Oil Red O (ORO), acid and alkaline phos-
phatase, NADH, COX, SDH and ATPase at pH 4.3, 4.6 and 9.4, as
reported elsewhere [24]. In addition some immunohistochemistry
reactions such as class I antigens from the MHC as well as p62
were performed. The same expert pathologist (J.M.G.) read all the
samples. Leftover biopsy material from both sIBM patients and
individuals with no histological myopathy was included as patient
and control samples, respectively. Histological data were collec-
ted to study inflammation and the presence of ragged-red fibres,
COX-negative and SDH-positive fibres, as well as the number
of vacuolated muscle cells. Diagnosis of sIBM was considered
as definite or probable according to the criteria of the European
Neuromuscular Centre [1,25]. Samples from 23 muscle biopsies
from sIBM patients and 18 from controls were included follow-
ing these criteria. In parallel, blood samples were collected from
14 sIBM patients and 20 control individuals free of muscle dis-
ease. Exclusion criteria were: age <40 years, muscle disease in
the case of controls, mitochondrial disease, and family history of
hereditary mitochondrial pathology, HIV infection or drug abuse.
All individuals were informed, and signed written consent was
obtained for inclusion in this study, which was approved by the
Ethical Committee of our hospital, following the Declaration of
Helsinki. All sIBM patients answered the Inclusion Body Myos-
itis Functional Rating Scale (IBMFRS) test, which is a validated,
disease-specific test to assess disease severity.
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A database was created to collect epidemiological, clinical
and histological data, which were further complemented with
experimental results.
Leftover samples from mandatory muscle biopsy diagnosis
were included in optimal cutting temperature compound (OCT)
and immediately frozen and stored at −80 ◦C until homogeniza-
tion (5% w/v) with mannitol to perform experimental studies.
Around 20 ml of peripheral blood was also obtained by
antecubital vein puncture and collected in EDTA tubes. PBMCs
were isolated using Ficoll density gradient centrifugation, divided
into aliquots and stored at −80 ◦C until analysis.
Mitochondrial genetic studies
Total DNA from muscle biopsies and PBMCs was obtained
by the standard phenol–chloroform extraction proced-
ure. The assessment of mtDNA deletions was performed
in muscle samples by long-range PCR using Phusion
High-Fidelity PCR Master Mix with GC Buffer (F-532L,
ThermoFisher Scientific) and the following primers: for-
ward 5′-TTAGCAAGGGAACTACTCCCA-3′ and reverse
5′-CGGATACAGTTCACTTTAGCTACCCCCAAGTG-3′. The
methodology of this procedure was performed as previously
described [26–28]. The PCR products were electrophoresed in a
0.8% agarose gel with ethidium bromide to detect different sizes
in the mitochondrial genome (see Supplementary Figure S1).
To evaluate mtDNA content, fragments of the mitochondri-
ally encoded 12S rRNA gene and the nuclear-encoded RNase-P
gene were amplified separately in triplicate by quantitative reverse
transcriptase PCR (RT-PCR) using Applied Biosystems techno-
logy [29]. The relative mtDNA content was expressed as the ratio
mtDNA 12S rRNA:nDNA RNase-P.
Mitochondrial transcript quantification
To evaluate mtRNA content in both muscle and PBMCs, total
RNA was first extracted using the TriPure procedure and im-
mediately retro-transcribed into cDNA using random hexamer
primers, following previously described methodology [30]. The
mtRNA:nRNA content was then measured by RT-PCR as pre-
viously described for mtDNA and expressed in the same units
(mtRNA 12S rRNA:nRNA RNase-P).
Mitochondrial protein quantification
Mitochondrial protein quantification was assessed in muscle
and PBMCs by the quantification of two mitochondrial com-
plex IV protein subunits: COX-II (encoded by the mitochon-
drial genome) and COX-IV (encoded by the nuclear genome).
These proteins were assessed through immunoblotting using
SDS/7/13% PAGE and immunodetection using previously de-
scribed reagents and antibodies [22]. Mitochondrial values nor-
malized to nuclear-encoded COX proteins were expressed as
the COX-II:COX-IV ratio, and absolute values of COX-II and
COX-IV were normalized with a loading control (α-tubulin for
muscle samples and β-actin for PBMC samples) and expressed
as the COX-II:α-tubulin and COX-IV:α-tubulin ratios in muscle
or the COX-II:β-actin and COX-IV:β-actin ratios in PBMCs.
COX-II and COX-IV values were also normalized by mitochon-
drial mass [through constitutive voltage-dependent anion channel
1 (VDAC1) expression] and expressed as COX-II:VDAC1 and
COXIV:VDAC1 ratios in both tissues (see Supplementary Figure
S2) [31].
MRC complex I and complex IV enzyme activity
MRC complex I (EC 1.6.5.3) and IV (COX – EC 1.9.3.1) enzyme
activities were measured spectrophotometrically according to the
methodologies of Spinazzi et al. [32] in both muscle homogen-
ates and PBMCs. Specific enzymatic activities were expressed in
absolute values as nanomoles of substrate consumed or product
generated per minute per milligram of cell protein (nmol/min per
mg protein) or in relative values with respect to mitochondrial
content normalized by citrate synthase (CS) activity (COX:CS).
MRC complex assembly
Total oxidative phosphorylation rodent WB Antibody Cocktail
(MS604, Abcam) was used to detect one subunit from each MRC
complex (I–V): NDFUFB8 from complex I, SDHB from complex
II, UQCRC2 from complex III, MTCO1 from complex IV and
ATP5A from complex V. These subunits are labile when the
respiratory complex to which they belong is not assembled and
a decrease in this subunit would manifest this phenomenon. To
normalize the levels of expression of these five proteins from
the MRC we analysed using the SYPRO technique for the total
protein content and the VDAC1 levels for the mitochondrial mass
in the same membrane.
Mitochondrial mass analysis
Mitochondrial mass was analysed in both muscle and PBMCs
by spectrophotometric measurement of CS (EC 4.1.3.7) enzyme
activity and, in parallel, by the measurement of VDAC1 pro-
tein levels by Western blotting. CS is a mitochondrial enzyme
of the citrate cycle widely considered to be a reliable marker
of mitochondrial content, and VDAC1 [22] is an outer mem-
brane anion channel also considered to be a mitochondrial mass
marker [22]. CS activity was expressed as nmol/min per mg of
protein and VDAC1 expression was normalized by α-tubulin in
muscle and by β-actin in PBMCs, both of which are validated
proteins for assessing total cell loading mass and expressed as the
VDAC1:α-tubulin ratio in muscle or the VDAC-1:β-actin ratio in
PBMCs.
Oxidative stress assay
Lipid peroxidation (an indicator of oxidative damage produced by
ROS in cellular lipid compounds) was quantified in muscle and
PBMCs using the Oxys Research kit (Deltaclon) through the
spectrophotometric measurement of malondialdehyde (MDA)
and 4-hydroxyalkenal (HAE), both products of fatty acid per-
oxide decomposition and normalized by protein content (μM
MDA + HAE per mg of protein) [33].
Expression of mitochondrial fusion proteins
Mitochondrial dynamics were assessed in muscle tissue by the
evaluation of both optic atrophy 1 (OPA1) and mitofusin 2
(MFN2) expression at two different levels: transcript and protein
quantification. For the assessment of transcript levels of OPA1
and MFN2, mRNA, total RNA extracted by TriPure was reverse
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transcribed with the SuperScript III reverse transcriptase kit (In-
vitrogen). Quantitative PCRs were performed with ABI Prism
7900HT real-time PCR equipment (Applied Biosystems) using
materials and reagents previously described [34,35]. All meas-
urements were normalized to glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNA content. Protein levels of OPA1
and MFN2 were assessed in parallel using Western blotting on
SDS/7/8% PAGE and posterior immunodetection using a BD an-
tibody (612606) and an Abcam antibody (ab56889), respectively.
In the case of OPA1, results were expressed as the ratio between
the long and the short forms of the protein (OPA1 long:short),
because this ratio decreases in abnormal mitochondrial dynamic
states. In the case of MFN2, absolute values were normalized
by total cell loading mass and expressed as the ratio MFN2:α-
tubulin.
Statistical analysis
Statistical analysis was performed using the SPSS, version 20.00
to search for differences depending on group assignment (patients
vs controls or presence vs absence of mtDNA deletions) using the
non-parametric Mann–Whitney U-test for independent samples.
Results were expressed as means +− S.E.M.S or as a percentage
of increase/decrease with respect to controls that were arbitrarily
assigned as 0%. In all cases, P < 0.05 was considered statistically
significant.
RESULTS
Clinical and histological data
According to the design of the study, no statistical differences
were observed with regard to age and gender between sIBM
patients and controls. Clinical, epidemiological, histological
and mtDNA deletion data of both patients and controls
are summarized in Table 1 and histological data examples
are compiled in Figure 1. At the time of study inclusion
the sIBM patient cohort scored 26.61 +− 1.19 out of 40 with the
IBMFRS test, indicating moderate-to-advanced sIBM clinical
severity.
MtDNA deletions
When assessing for the presence of mtDNA deletions in muscle
from sIBM patients, 57% of the sIBM cohort presented multiple
mtDNA deletions, whereas the rest showed no alterations in this
parameter (see Supplementary Figure S1).
MtDNA content
MtDNA content was significantly decreased by 36% in muscle
from sIBM patients compared with controls (641.6 +− 141.2
vs 979.7 +− 111.3, respectively, P < 0.05) (Figure 2). Similarly,
mtDNA was decreased, albeit not significantly, by 14.5% in PB-
MCs (Figure 2).
Mitochondrial transcript quantification
No variation was found in the levels of mtRNA in either muscle
or PBMCs (Figure 2) of sIBM patients compared with controls.
Table 1 Clinical, epidemiological and histological data of
patients with sIBM and controls included in the present study
Muscle biopsies sIBM (n=23) Controls (n=18)
Clinical and epidemiological data
Age (years)a 68.64 +− 2.87 63.22 +− 2.55
Male:female ratio 0.64 0.38
IBMFRS scorea 26.61 +− 1.19/40 –
mtDNA deletions (%)b 57 –
Histological data (%)
Rimmed vacuolesb 61.20 –
Ragged-red fibresb 60 –
COX-negative fibresb 36.36 –
SDH-positive fibresb 44 –
MHC-I expressionb 57.14 –
Inflammationb 67.74 –
PBMC samples sIBM (n=14) Controls (n=20)
Clinical and epidemiological data
Age (years)a 68.43 +− 3.28 68.55 +− 1.41
Male:female ratio 1 1.85
IBMFRS scorea 25.85 +− 1.31/40 –
aData presented as means +− S.E.M.s.bData presented as percentage.
Mitochondrial protein quantification
As shown in Figure 2, muscle from sIBM patients presented
an increase of 25% in the COX-II:COX-IV ratio with respect
to controls, suggesting increased expression of mitochondrial
versus nuclear COX subunits (see Supplementary Figure S2). It
is interesting that in PBMCs this ratio showed a statistically signi-
ficant decrease of 45.46% (0.42 +− 0.05 vs 0.77 +− 0.09, P < 0.05;
Figure 2). In addition, in PBMCs COX-IV protein levels normal-
ized by total cell mass showed a strong trend to be increased by
67.85% in sIBM patients compared with controls (0.47 +− 0.08 vs
0.28 +− 0.03, P = 0.064; Figure 2), suggesting increased nuclear
versus mitochondrial COX protein expression. This abnormal-
ity became statistically significant when COX-IV values were
normalized by mitochondrial mass (COX-IV:VDAC-1), which
showed a 172.72% increase in sIBM patients compared with
controls (1.80 +− 0.35 vs 0.66 +− 0.01, P < 0.05; Figure 2).
Mitochondrial complex I and IV activity
Measurements of respiratory chain activities showed no differ-
ences in complex I activity in muscle of patients and controls,
in either absolute or relative units (data not shown). However,
complex IV activity was abnormally decreased in both muscle
and PBMCs of sIBM patients with respect to controls (Figure 2).
Thus, taking into account absolute values, a decrease of 13.55%
was found in muscle (Figure 2). These differences became stat-
istically significant in muscle when complex IV activity was nor-
malized to mitochondrial mass (CS), by showing a 30.31% de-
crease in sIBM patients compared with controls (0.26 +− 0.02 vs
0.33 +− 0.03, P < 0.05; Figure 2). On analysing this parameter in
PBMCs, complex IV activity was also significantly decreased
by 31.4% in absolute values in patients compared with controls
(24.32 +− 3.1 vs 35.45 +− 3.4, P < 0.05; Figure 2) and by 28.21%
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Figure 1 Images from the histological staining of sIBM muscle tissue
(A, B) H&E in frozen muscle tissue: marked variability in fibre size. Some inflammatory cells are observed in the en-
domysium, together with rimmed vacuoles (arrows) and a typical ragged-red fibre (star). (C) Almost universal sarcolemmal
positivity of class I antigen from the MHC, a typical feature in sIBM. (D) Positivity of p62 in rimmed vacuoles, suggestive
of muscle degeneration. Scale bar=50 μm.
Figure 2 Mitochondrial parameters in muscle and PBMCs from sIBM patients compared with controls
Mitochondrial parameters in muscle tissue and PBMCs from patients with sIBM expressed as percentage of in-
crease/decrease compared with controls. A significant decrease in mtDNA amount and complex IV activity normalized
to mitochondrial content can be observed in muscle, and also a significant decrease in COX-II:COX-IV ratio, complex IV
absolute activity and complex IV activity normalized to mitochondrial content can be observed in PBMCs. In this muscle
tissue, a significant increase in COX-IV subunit normalized to mitochondrial content can be observed as well as other
non-significantly altered parameters. α-t, α-tubulin; β -a, β -actin; C-IV, MRC complex IV. * : p < 0.05.
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when this parameter was normalized to the mitochondrial mass
(0.28 +− 0.1 vs 0.39 +− 0.1, P < 0.05; Figure 2).
MRC complexes assembly
The analysis of the subunit levels for each complex of the MRC
(I–V) that correlates with the proper assembly of the respiratory
chain complexes did not show differences between sIBM patients
and controls, normalized to either total protein or VDAC1 con-
tent. It is interesting that the complex V subunit presented a trend
towards a decrease in sIBM patients, but this difference did not
reach statistical significance (Figure 3).
Mitochondrial mass content
Mitochondrial mass, assessed by both the quantification of CS
enzyme activity and VDAC1 protein content, was increased in
muscle of sIBM patients compared with controls (12.9% in CS
activity and 18.7% in VDAC1:α-tubulin protein levels; see Fig-
ure 2) and decreased in PBMCs of sIBM patients compared with
controls (by 24.18% in CS activity and 23.26% in VDAC1:β-
actin protein content; see Figure 2). However, none of these results
was statistically significant.
Oxidative stress levels
No differences were found in lipid peroxidation, an indicator of
oxidative damage produced by ROS in lipid compounds, between
sIBM patients and controls in muscle or PBMCs (see Figure 2).
Quantification of mitochondrial dynamics
Transcript levels of OPA1 showed a significant 37% reduction
in muscle of sIBM patients compared with controls (0.59 +− 0.11
vs 0.94 +− 0.19, P < 0.05; Figure 4). OPA1 long:short protein iso-
form ratios, although not significant, were decreased by 45% in
muscle of sIBM patients compared with controls (0.55 +− 0.17 vs
1 +− 0.16, P < 0.083; Figure 4). In the case of MFN2 transcripts,
muscle of sIBM patients showed a 31% reduction. With regard to
MFN2 protein expression, a strong trend towards a decrease was
observed in sIBM patients, with 54% compared with controls
(1.93 +− 0.3 vs 4.17 +− 0.1, P = 0.096; Figure 4). The differences
in MFN2 levels in either transcript or protein content were not
statistically significant.
Correlation of mitochondrial parameters with regard
to the presence/absence of mtDNA deletions
Last, the sIBM cohort was divided into two groups on the basis of
the presence or absence of mtDNA deletions for further explora-
tion of mitochondrial homoeostasis, depending on this condition
with respect to controls. The mtDNA content was slightly de-
creased in sIBM patients with mtDNA deletions compared with
those without (Figure 5). These differences became statistically
significant in sIBM patients with deletions with respect to the
control group (498.50 +− 178.70 vs 979.70 +− 111.38, P < 0.05).
MFN2 levels showed a similar pattern to those of mtDNA con-
tent, showing the lowest content in sIBM patients with mtDNA
deletions and the highest in controls (1.16 +− 0.24 vs 4.17 +− 0.96,
P < 0.05), with sIBM patients without mtDNA deletions present-


































































Figure 3 MRC complex assembly through the measurement of
protein expression level of labile subunits of each complex in
muscle tissue from sIBM patients compared with controls
No significant differences with regard to levels of specific subunits for
each MRC complex were found between muscle from sIBM patients and
muscle from controls, normalized to (a) total protein content and (b) the
nuclear-encoded mitochondrial protein VDAC1. A trend towards increase
is observed in the complex V subunit when normalized to VDAC1 which,
although not significant, may give us an idea of complex V disassembly.
This multiplex Western blotting measures the protein expression level
of a subunit of each MRC complex (I–V), labile when the complex is
not properly assembled; the following were measured: NDFUFB8 from
complex I (CI; 20 kDa), SDHB from complex II (CII; 30 kDa), UQCRC2
from complex III (CIII; 48 kDa), MTCO1 from complex IV (CIV; 40 kDa)
and ATP5A from complex V (CV; 55 kDa).
DISCUSSION
Mitochondrial abnormalities in muscle from sIBM patients are
accepted in the scientific community as a result of histological
evidence [7,36]. However, little research has been performed to
characterize potential functional or molecular mitochondrially
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Figure 4 Mitochondrial dynamics in muscle from sIBM patients
MFN2 and OPA1 were assessed in muscle from sIBM patients at the transcript and protein levels. Significant differ-
ences were found when OPA1 mRNA levels were compared between the two groups. The other parameters showed a
non-significant trend to be decreased in the sIBM respective controls. * : p < 0.05.
disrupted pathways [6–8]. In the present study, we evaluated mi-
tochondrial dysfunction at a genetic and molecular level, and
studied its potential association with mitochondrial dynamic de-
regulation. We compared mitochondrial status in muscle and PB-
MCs from sIBM patients with that of controls, first to evaluate
its involvement in disease aetiology and, second, to determine
whether mitochondrial alterations are confined to muscle tissue
(the target tissue of the disease) or whether these alterations
extend to other body tissues, which may allow less invasive ap-
proaches and potential follow-up as a putative biomarker.
With regard to experimental data, sIBM patients showed a
decrease in mtDNA content. This mtDNA depletion was stat-
istically significant in muscle from sIBM patients, because it
is post-mitotic tissue that is prone to store mitochondrial defi-
ciencies. On the other hand, mtDNA depletion was only mildly
manifested in PBMCs, probably due to their higher renewal capa-
city and shorter mean lifespan. Although mtDNA depletion was
found in both tissues, no significant changes were observed in
mtRNA levels of either muscle or PBMCs [37].
On analysing MRC function, no differences were found in
complex I activity in muscle from sIBM patients compared with
controls. Otherwise, MRC complex IV deficiency was present
in both tissues (muscle and PBMCs) of sIBM patients. Abso-
lute values of complex IV activity in muscle showed a trend
towards a decrease, but, on normalizing these absolute values by
mitochondrial mass, complex IV deficiency became significant.
These phenomena may be due to the increase in mitochondrial
biogenesis detected in muscle of sIBM patients as compens-
ating for mitochondrial dysfunction. This increase in muscular
mitochondrial content, characteristic of primary mitochondrial
diseases [38], is observed in parallel in sIBM patients as an
increase in CS activity and VDAC1:β-actin protein levels, as
well as by the presence of ragged-red fibres. Similarly, mito-
chondrial protein synthesis tended to increase, albeit not signi-
ficantly, in muscle from sIBM patients (COX-II:COX-IV), prob-
ably as a consequence of the trend of this homoeostatic muscle
to increase mitochondrial biogenesis. As mentioned previously,
PBMCs present a shorter mean lifespan, thereby hindering the
development of homoeostatic mechanisms such as increasing mi-
tochondrial content to deal with mitochondrial dysfunction. Thus,
in PBMCs, complex IV activity was found to be significantly de-
creased in both absolute and relative values to mitochondrial
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Figure 5 MtDNA amount and MFN2 protein levels in muscle of
sIBM patients with and without mtDNA deletions and controls
Comparison of (a) mtDNA amount and (b) MFN2 levels among patients
with sIBM with and without mtDNA deletions and controls. The patients
with sIBM and mtDNA deletions showed significantly reduced muscle
levels of mtDNA and MFN2 protein levels with respect to the controls.
The patients with sIBM and no mtDNA deletions presented an inter-
mediate value, suggesting the implication of mtDNA deletions in other
mitochondrial alterations or the involvement of mitochondrial dynamics
in mtDNA homoeostasis. * : p < 0.05.
mass, which additionally showed trends towards a decrease, ac-
cording to poor homoeostatic compensation. Unlike in muscle,
in PBMC nuclear-encoded protein subunits of COX (COX-IV)
were slightly increased to compensate for COX dysfunction. The
trends towards up-regulation of mitochondrially encoded proteins
in muscle or nuclear-encoded proteins in PBMCs, to compensate
for MRC dysfunction, may depend on the levels of endoplasmic
reticular stress of both cell types, which has been reported to be
altered in muscle [39,40].
Mitochondrial dysfunction in sIBM patients is not caused
by abnormal assembly of MRC complexes, at least as assessed
through the measurement of protein levels of specific subunits
that are labile in cases of complex instability. However, there was
a strong trend of the complex V subunit, when normalized to
mitochondrial mass, to be decreased. This decrease disappeared
when the complex V subunit content was normalized to total cell
protein. This could be explained by the slight increase in mito-
chondrial mass that underlies sIBM. Further analysis of complex
V activity could be useful to elucidate whether this complex is
altered in this disease.
Oxidative stress does not seem to play a role in sIBM patho-
genesis, because lipid peroxidation levels are not increased in
muscle or PBMCs from sIBM patients, at least in the present
study cohort.
Overall, these data describe an altered mitochondrial pheno-
type in muscle and PBMCs of sIBM patients, with both tissues
presenting a different lesion profile, probably due to different
compensatory mechanisms related to the disease. It is interesting,
regardless of the homoeostatic attempt to preserve mitochondrial
function, that COX enzymatic deficiency is present in both tissues
as a common pathogenic parallelism. Thus, it seems that mito-
chondrial dysfunction in sIBM is not confined only to the target
tissue of the disease, muscle, but may also extend to other body
tissues. Whether COX/CS activity could be used as a prognostic
or severity biomarker of the disease should be assessed in further
studies. Alternatively, PBMC mitochondrial alterations may be
interpreted as a deregulation of the immune system, non-specific
for sIBM, as stated before for other diseases with inflammatory
components [41–45]. Regardless of the interpretation, mitochon-
drial impairment is present in both PBMCs and muscle tissue of
sIBM patients.
Mitochondrial dynamics are the mechanism for this organ-
elle recycling and turnover. Imbalance of proper ratios of fu-
sion and fission events has recently been associated with dis-
ease [13,46,47]. Mitochondrial dynamics were severely altered
in muscle of sIBM patients as demonstrated by the decreased
expression of OPA1 and MFN2 transcript and protein levels.
Deregulation of the mitochondrial fusion:fission ratio leads to
abnormal mitochondrial turnover, which is essential for the re-
cycling of damaged and dysfunctional mitochondria [48], such
as those characteristic of sIBM patients.
It is interesting that reduced expression of MFN2 in sIBM pa-
tients is associated with abnormal mitochondrial genetics (both
deletions and depletion). Previous studies have reported the
strong dependence of mtDNA maintenance on proper mitochon-
drial dynamics in physiological conditions [10]. This is the first
study to report this association in the context of sIBM disease.
Whether mitochondrial genetic and molecular alterations lead
to abnormal mitochondrial dynamics or, on the contrary, to an
1748 C© 2016 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
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imbalance in mitochondrial dynamics underlying the mitochon-
drial genetic and molecular disturbances is still a matter of debate.
In any case, both adverse conditions seem to go hand in hand with
the development of sIBM disease.
In summary, in the present study we demonstrate that mito-
chondria are impaired in sIBM, not only at histological but also
at genetic, molecular and functional levels, confirming the in-
volvement of mitochondria in the aetiology of this disease. The
lesion is characterized by different patterns in both muscle and
PBMCs of sIBM patients, demonstrating that mitochondrial in-
jury is not exclusive to the target tissue of the disease but is also
present in peripheral tissues. It is interesting that mitochondrial
COX activity normalized by mitochondrial mass is altered in
both tissues, highlighting the relevance of this parameter, and the
need for further studies on this as a putative candidate diagnostic
tool or therapeutic target. In addition, deregulation in mitochon-
drial dynamics seems to be crucial for mtDNA stability, not only
in healthy conditions [10] but also in sIBM disease. Deregula-
tion of mitochondrial dynamics in muscle leads to increased ge-
netic alterations such as mtDNA depletion and multiple deletions,
demonstrating that mitochondrial turnover is essential for proper
mitochondrial health and, furthermore, for muscle function. Al-
though further investigation is needed to demonstrate whether
mitochondrial alterations are primary or secondary in sIBM, the
present study provides more in-depth understanding of the role of
mitochondria in this disease. It also provides knowledge related
to the mechanisms implicated in order to help develop new dia-
gnostic tools or therapeutic targets for this disease, in the absence
of non-invasive diagnostic tools or effective therapy.
CLINICAL PERSPECTIVES
• The better understanding of how mitochondria is in sIBM
would be useful at clinical level at different levels: to confirm
that mitochondrial changes seen in the muscle biopsy of sIBM
patients is a solid marker to help diagnose this disease.
• This information could be useful to develop new therapeutical
strategies to treat muscle dysfunction in sIBM patients.
• The knowledge about the pathogenic mechanisms of the dis-
ease allow us to elaborate a more accurate description of the
disease for the patient, as they could be able to know about
the disease they’re suffering.
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